Released Nov 12, 2026, before the open
10-Q filed Nov 12, 2026, 43 days after period end · 0001326190-26-000070
On November 12, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its third quarter ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | — | $5.00K | $5.00K | $362.00K |
| Net Income | -$31.61M | -$19.01M | -$22.85M |
Altimmune, Inc. · CIK 1326190 · Engraved from SEC EDGAR
| -$20.67M |
| EPS Diluted | -$0.15 | -$0.21 | -$0.32 | -$0.39 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Altimmune reported a net loss of $31.6 million, or $0.15 per share, for the three months ended September 30, 2026, compared to a net loss of $19.0 million, or $0.21 per share, in 2025.¶2
Research and development expenses rose to $27.0 million from $15.0 million, driven primarily by the PERFORMA Phase 3 trial in MASH and the RESTORE Phase 2 trial in ALD.¶2
General and administrative expenses were $8.7 million, compared to $5.9 million a year earlier, driven primarily by higher compensation and professional services expenses.¶2
Altimmune reported cash, cash equivalents and investments totaling $480 million as of September 30, 2026.¶3¶2